ガイドビュー
遺伝学が初めてですか？ 閲覧しながら、すべての用語をわかりやすく説明します。同じページに、サポートが組み込まれています。
専門家の見解
生物学はすでにご存知の方へ。コンテンツだけをすっきりとコンパクトに、余分な説明なしでお届けします。これがデフォルト表示です。
CRISPR Decoded は独自のニュースを報道していません。以下の見出しはすべて、隣に記載された出版社に帰属し、新しいタブでその出版社のウェブサイトが開きます。そちらの利用規約、ペイウォール、トラッキングが適用されます。送信前にご確認いただきます。
Human cells hold about two meters (6.6 feet) of DNA, folded and compacted to fit inside a nucleus. That packing is essential for life, but it creates a problem for scientists. Some of the genes that control a cell's identity are buried so deep in tightly packed DNA that gene-targeting tools such as…
Medical Xpress — Genetics
Huntington's disease is caused by repetitive "stutters" in DNA—specifically repeated CAG sequences—that expand abnormally over time, leading to toxic protein accumulation that…
Medical Xpress — Genetics
Peter Mac scientists have developed a way to precisely target the "unique molecular fingerprint" created when two genes become abnormally fused together, a discovery that could…
In this GEN webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to…
Synthetic Biology5,812 protein groups were quantified in postmenopausal ovaries, uncovering molecular shifts associated with inflammation, immunity, and extracellular matrix remodeling. The post Proteomics…
Bacteriophages, or viruses that infect bacteria, have a fiendishly simple purpose in life: attach to a bacterial cell, inject their DNA and then use the host's genetic machinery to…
Some people are born with a defect in their genetic material that prevents their immune system from functioning properly. In people with a condition known as GATA2 deficiency, the body does…
Prime EditingA new antiviral defense system discovered by Columbia scientists could be adapted in the future into a gene editor that slows down aging in our cells and improves cancer therapies. At the…
CancerA study in Cameroon found that sickle cell trait is associated with distinct malaria parasite genotypes, potentially explaining reduced disease risk despite similar infection rates. The…
Malaria is one of the deadliest infectious diseases on the planet, afflicting people throughout recorded history. In places where malaria is most common, it's shaped human evolution by…
Scientists at UC San Francisco have developed a way to create cancer-fighting CAR-T cells directly inside the body, potentially avoiding the slow and extremely expensive process of…
CancerSequencing by expansion (SBX) and Roche’s AXELIOS 1 platform introduce a new approach to single-molecule sequencing, designed to give researchers flexibility across sequencing workflows…
How do bacteria adapt when resources run low? ISTA researchers have found that, under starvation stress, E. coli can use bacteriophages and CRISPR-Cas immunity to transfer and incorporate…
Predictive cell intelligence can be used to reveal cellular states and emerging cellular trajectories earlier in the manufacturing process and to support more informed bioprocessing…
The assembly pathway behind refractile-body proteins may have finally been resolved, researchers from Science Tokyo report. Using genetic engineering and several techniques for analyzing…
AI-assisted genomic analysis was combined with human genetics and fruit fly experiments to link reduced BRSK1 function to a variable neurodevelopmental disorder. The post AI Tool Helps Link…
Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a…
Leukemia and Lymphoma CancerA synthetic biology technology has been developed that converts easily degraded messenger RNA (mRNA) into a ring-shaped form inside microbial cells, increasing protein production.
Synthetic BiologyCRISPR may be a powerful technology for gene editing, but the system existed in bacteria long before scientists began using it. For billions of years, CRISPR has acted as a natural immune…
A new genome-editing method, prime assembly, precisely inserts long DNA sequences into targeted genomic locations, potentially enabling mutation-agnostic gene therapies for diverse genetic…
Rather than requiring genetic modification of the viral glycoprotein, G-Link uses a modular protein adaptor to blind native VSV-G tropism and redirect delivery after vector production. The…
A research team from The Hong Kong University of Science and Technology (HKUST) has developed an innovative "one-pot" testing platform, known as TEMPO, that could transform highly sensitive…
The ability to precisely adjust the expression of genes inside the human body—ramping up protective ones and tamping down harmful ones—holds enormous potential for treating and preventing…
Martha’s Vineyard Hospital launches a two-year study tracking up to 300 residents to understand who develops alpha-gal syndrome after lone star tick exposure and why. The post Pioneering…
A study in mice found that male sex hormones can suppress allergic responses by promoting sympathetic nerve connections and norepinephrine release in the lungs. The post Male Sex Hormones…
Scientists see a positive trend toward using AI in a way that’s human, rather than as a self-driving lab. AI is simply a tool—albeit a powerful, adaptive one. The post Protecting Scientific…
In this GEN webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing. The post…
Bacteria-killing phage viruses souped up with DNA-destroying CRISPR appear to have helped clear up a very serious infection caused by antibiotic-resistant E. coli
There is no majority support for use of gene editing on non-life-threatening conditions, writes Tom Lichy of the British Deaf Association Your editorial ( The Guardian view on gene-edited…
ジャーナリズムではありません。社内制作のコンテンツです
当サイト独自のデータベースレコードをもとにAIの支援で作成した短い要約です。他のメディアが報道したものではなく、署名もありません。そのため、上のニュースとは明確に分けて掲載しています。
CRISPR Decoded organises its 92 pages across four evidence levels, and the distinction matters because it signals how much human data sits behind any claim. Laboratory research, covering 5 pages, describes work done entirely in cells or computer models. No human has received anything at this stage. Preclinical research, covering 12 pages, adds animal studies but still involves no human trials. Both levels indicate that a technology or disease application is at an exploratory stage, and according to CRISPR Decoded records, conditions such as Parkinson's disease sit at laboratory research while Duchenne muscular dystrophy remains preclinical. Clinical research is the largest category, with 59 pages. It covers every phase of human trials, from first-in-human Phase I studies through to Phase III registrational programmes. Being in clinical research means human data exists, but it does not mean a therapy is proven safe, effective or available. Approved treatment, covering 16 pages, is reserved for therapies that have cleared regulatory review. According to CRISPR Decoded records, only one gene editing therapy, Casgevy, holds that status, making the approved category the narrowest and most consequential distinction of all.
16h agoApproved gene editing treatments exist today for sickle cell disease and beta thalassemia, and the records of CRISPR Decoded point to a shared reason: both diseases involve blood stem cells that can be removed from a patient, edited outside the body, and returned. This ex vivo approach sidesteps one of the hardest problems in the field, namely delivering editing machinery reliably to cells inside a living person. Casgevy, a CRISPR-Cas9 therapy, reached approval on exactly this basis. Conditions that require editing inside the body face a steeper path. The liver is relatively accessible via lipid nanoparticles, which is why ATTR amyloidosis and hereditary angioedema have reached Phase III. Tissues such as muscle, the central nervous system and the lung are harder to reach, and Duchenne muscular dystrophy, Huntington's disease and cystic fibrosis remain preclinical in these records. A 2025 death in the MAGNITUDE liver-targeting trial also illustrated a further constraint: an irreversible in vivo edit cannot be withdrawn if something goes wrong, raising the safety threshold regulators apply.
16h agoAccording to CRISPR Decoded records, the most recent developments span 2023 to 2026 and range from a landmark approval to the first positive Phase 3 result for in vivo gene editing. In November 2023, the UK MHRA authorised Casgevy, a CRISPR-Cas9 therapy, for sickle cell disease and beta thalassemia, with FDA authorisation following in December 2023 and January 2024. This represents an approved treatment, the highest evidence level recorded. In 2025, results from PM359 in chronic granulomatous disease provided the first clinical evidence for prime editing, rated clinical research: prime-edited stem cells engrafted and restored immune function. That same year, a participant in the Phase 3 MAGNITUDE trial of nexiguran ziclumeran died following severe liver injury, prompting a voluntary pause and an FDA clinical hold. The hold on MAGNITUDE was later lifted. In 2026, Intellia reported positive Phase 3 results, clinical research evidence, for lonvoguran ziclumeran in hereditary angioedema, described in CRISPR Decoded records as the first successful registrational trial of in vivo gene editing, with a licence application signalled for later that year.
16h agoAs reflected in CRISPR Decoded records, one gene editing treatment has reached regulatory approval: Casgevy, a CRISPR-Cas9 therapy for sickle cell disease and beta thalassemia, authorised first by the UK MHRA in November 2023 and subsequently by the FDA. Two approved lentiviral gene-addition therapies, Lyfgenia and Zynteglo, address the same blood disorders but use a different mechanism and are not gene editing. Four gene editing programmes have reached Phase III. Nexiguran ziclumeran targets ATTR amyloidosis, lonvoguran ziclumeran targets hereditary angioedema and reported the first positive Phase III result for in vivo gene editing, risto-cel uses base editing for sickle cell disease, and BEAM-302 applies base editing to alpha-1 antitrypsin deficiency. Several earlier-stage trials cover cancer, familial hypercholesterolemia, chronic granulomatous disease and diabetes. A significant portion of the broader landscape remains preclinical or at discovery stage, including programmes for Duchenne muscular dystrophy, cystic fibrosis, hemophilia, Huntington's disease, Parkinson's disease and Alzheimer's disease, underlining how much of gene editing's potential has not yet been tested in humans.
16h agoCRISPR Decoded が収集しているすべての出版社と、現在保持している記事数。
| 出版社 | 収録記事数 | 最新 |
|---|---|---|
| GEN — Genetic Engineering News | 65 | Oct 27, 2026 |
| Endpoints News | 50 | Oct 27, 2026 |
| Nature Genetics | 30 | Oct 26, 2026 |
| STAT | 24 | Oct 27, 2026 |
| Phys.org — Molecular Biology | 20 | Oct 27, 2026 |
| Medical Xpress — Genetics | 15 | Oct 22, 2026 |
| Science Daily — Gene Therapy | 6 | Sep 7, 2025 |
| The Guardian — Genetics | 6 | Sep 21, 2026 |
| Science Daily — Genes | 5 | Oct 7, 2026 |
| Science Daily | 2 | Aug 17, 2026 |
| New Scientist | 2 | Sep 25, 2026 |
| FDA | 2 | Sep 17, 2026 |
| MIT Technology Review | 2 | Aug 14, 2026 |
見出し、出版社名、リンクのみ。記事は記載された出版社の所有物です。日付は各フィードが報告する公開日で、UTC表示です。画像が表示される場合は出版社のサーバーから配信され、出版社に帰属します。
このリンクは私たちが運営していないウェブサイトを開きます。そのコンテンツ、正確性、または独自のCookieやトラッキングを含むデータの取り扱いを管理することはできません。そこで読んだ内容は私たちによるレビューを受けていません。